Bronchiectasis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 4 and 3 respectively for Bronchiectasis.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchiectasis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchiectasis - Overview 8
Bronchiectasis - Therapeutics under Development by Companies 9
Bronchiectasis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bronchiectasis - Products under Development by Companies 13
Bronchiectasis - Companies Involved in Therapeutics Development 14
Alitair Pharmaceuticals, Inc. 14
Bayer AG 15
Grifols, S.A. 16
Insmed Incorporated 17
Kamada Ltd. 18
Polyphor Ltd. 19
Raptor Pharmaceutical Corp. 20
Recipharm AB 21
Savara Inc. 22
Vertex Pharmaceuticals Incorporated 23
Bronchiectasis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
amikacin sulfate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ARD-3150 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ciprofloxacin hydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
doxofylline - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
erdosteine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Leukotriene-B4 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
levofloxacin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
POL-6014 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
POL-7080 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
vancomycin hydrochloride - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
VX-371 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Bronchiectasis - Dormant Projects 68
Bronchiectasis - Discontinued Products 69
Bronchiectasis - Product Development Milestones 70
Featured News & Press Releases 70
Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians 70
Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients 70
Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency 71
Mar 16, 2016: Raptor Announces Qualified Infectious Disease Product Designation for MP-376, Inhaled Levofloxacin 72
Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6 72
Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 73
Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 74
Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City 75
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia 76
Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation 77
Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis 78
Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 79
Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 80
May 20, 2014: FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic 80
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Number of Products under Development for Bronchiectasis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016 14
Bronchiectasis - Pipeline by Bayer AG, H2 2016 15
Bronchiectasis - Pipeline by Grifols, S.A., H2 2016 16
Bronchiectasis - Pipeline by Insmed Incorporated, H2 2016 17
Bronchiectasis - Pipeline by Kamada Ltd., H2 2016 18
Bronchiectasis - Pipeline by Polyphor Ltd., H2 2016 19
Bronchiectasis - Pipeline by Raptor Pharmaceutical Corp., H2 2016 20
Bronchiectasis - Pipeline by Recipharm AB, H2 2016 21
Bronchiectasis - Pipeline by Savara Inc., H2 2016 22
Bronchiectasis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Bronchiectasis - Dormant Projects, H2 2016 68
Bronchiectasis - Discontinued Products, H2 2016 69